Abstract
背景与目的凡德他尼是一种多靶点口服的小分子抑制剂，可同时作用于血管内皮生长因子受体、表皮生长因子受体、RET酪氨酸激酶转染中的重排，本研究旨在探讨凡德他尼治疗晚期复治肺腺癌患者的疗效和副反应。方法患者经过化疗和特罗凯治疗失败后，给予凡德他尼300 mg每日1次口服。结果5例患者中，2例（40%）最佳疗效达疾病稳定（stable disease, SD），3例（60%）疗效均为疾病进展（progressive disease, PD）。随访40个月，1例患者目前仍在随访中。中位无疾病进展时间（progression free survival, PFS）为2个月，平均总生存期（overall survival, OS）为22.6个月。出现副反应包括皮疹（n=2）、皮肤改变（n=2）、甲沟炎（n=2）、无症状的心电图QTc延长（n=2）、ST-T改变（n=1）、腹泻（n=1）、转氨酶增高（n=1）。结论凡德他尼治疗晚期复治肺腺癌患者中位PFS为2个月，平均OS为22.6个月，具有较好的安全性，结果同相关文献报道类似。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
